AZCERT's scientific Review Committee has evaluated the available evidence for the recently marketed anti-cancer drug Glasdegib. Because of strong evidence that this drug prolongs the QT interval but at this time lacks evidence of torsades de pointes, AZCERT added Glasdegib to the Possible Risk of Torsades de pointes. Glasdegib was also added to the list of Drugs to Avoid (if feasible) in patients with congenital long QT. The drug is marketed in the US under the brand name Daurismo and approved for the treatment of acute myeloid leukemia. The drug label includes detailed recommendations for how to monitor the QT during therapy and includes cautions for patients with QT prolongation, inherited or acquired.